Staar surgical: independent industry analysts recognize merits of alcon merger, the value it provides, and the downside risks facing staar on standalone basis

Lake forest, calif.--(business wire)--staar surgical company (nasdaq: staa), the global leader in phakic iols with the evo family of implantable collamer® lenses (evo icl™) for vision correction, today highlighted commentary from numerous independent industry analysts who recognize that staar's merger with alcon (six/nyse: alc) – and the compelling, certain, premium cash value it provides – is the best path forward for staar stockholders. stephen farrell, ceo of staar, said, “prior to the alcon.
ALC Ratings Summary
ALC Quant Ranking